



# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	CATION NO. FILING DATE FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/616,950	07/11/2003	Markus Gewehr	AM 200040	2161	
26474 7	590 . 02/28/2006		EXAMINER		
	UCE DELUCA & QUIG	QAZI, SABIHA NAIM			
1300 EYE STR SUITE 400 EA			ART UNIT	PAPER NUMBER	
WASHINGTO	N, DC 20005	1616			
			DATE MAILED: 02/28/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

			Application N	0	Applicant(s)	<del></del>			
		-	10/616,950		GEWEHR ET AL.				
Office Action Summary			Examiner	<del></del>	Art Unit				
			Sabiha Qazi		1616				
The MAIL Period for Reply	ING DATE of this commu	nication appe		ver sheet with the c		Idress			
A SHORTENED WHICHEVER IS - Extensions of time ri after SIX (6) MONTH - If NO period for reply - Failure to reply withi Any reply received b	STATUTORY PERIOD IN LONGER, FROM THE IN LONGER, FROM THE IN LONGER AND LONGER	MAILING DA s of 37 CFR 1.13 munication. statutory period wi y will, by statute,	TE OF THIS ( 6(a). In no event, h ill apply and will exp cause the application	COMMUNICATION owever, may a reply be tirr ire SIX (6) MONTHS from n to become ABANDONE	I. lely filed the mailing date of this c (35 U.S.C. § 133).				
Status									
1) Responsiv	e to communication(s) fil	ed on <i>19 Jai</i>	nuary 2006						
· <u> </u>	• •			inal.					
<u> </u>	· · · · · · · · · · · · · · · · · · ·								
<i>,</i> —	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
Disposition of Clai	ns								
4)⊠ Claim(s) <i>1</i>	.2.4 and 5 is/are pending	in the applic	cation.						
· · · · · ·	) Claim(s) <u>1,2,4 and 5</u> is/are pending in the application.  4a) Of the above claim(s) is/are withdrawn from consideration.								
	is/are allowed.								
6)  Claim(s) <u>1, 2, 4 and 5</u> is/are rejected.									
· <u> </u>	are subject to restri	ction and/or	election requi	rement					
	•		olodion roqui	omon.					
Application Papers									
·	cation is objected to by th								
	g(s) filed on is/are	• —							
	ay not request that any obje								
Replaceme	nt drawing sheet(s) including	g the correction	on is required if	the drawing(s) is obj	ected to. See 37 CF	FR 1.121(d).			
11) The oath o	declaration is objected t	o by the Exa	aminer. Note t	ne attached Office	Action or form PT	O-152.			
Priority under 35 U	S.C. § 119								
a)∏ All b)[	gment is made of a claim ]Some * c)∐ None of:		-		-(d) or (f).				
1.☐ Cert	ified copies of the priority	documents	have been re	ceived.					
2.☐ Cert	ified copies of the priority	documents	have been re	ceived in Application	on No				
3.☐ Cop	es of the certified copies	of the priorit	ty documents	have been receive	d in this National	Stage			
appl	ication from the Internation	onal Bureau	(PCT Rule 17	.2(a)).					
* See the atta	ched detailed Office action	on for a list o	of the certified	copies not receive	d.				
Attachment(s)									
Notice of Reference	es Cited (PTO-892)		4) [	Interview Summary (					
	son's Patent Drawing Review (F	چ، ٦	Paper No(s)/Mail Date						
Paper No(s)/Mail D	ure Statement(s) (PTO-1449 or ate	P1U/SB/08)	′=	5)  Notice of Informal Patent Application (PTO-152) 6) Other:					

Application/Control Number: 10/616,950 Page 2

Art Unit: 1616

# Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 01/19/06 has been entered.

Claims 1, 2, 4, and 5 are pending. No claim is allowed. Amendments are entered.

This application claims priority from 60/394932, filed on July 11, 2002. Terminal disclaimer has been filed for U.S. Patent No. 6,521,628 and U.S. Patent No. 6,734,202 therefore double patenting rejection is withdrawn. DP rejection over US Patent 6,696,497 is maintained because no disclaimer was filed. Examiner notes, that Applicants are silent over this rejection.

## Response to Arguments

- Applicant's argument and declaration filed on January 19 has been fully considered but
  was not found persuasive. The data was not found convincing because the controlling
  Pseudocercosporella herpotrichoides is known. Whether it grow is grows in plant tissues
  or on the surface of the leaves, the compound is useful to control Pseudocercosporella
  herpotrichoide.
- It is not clear from the declaration that why one would not be motivated to use the presently compound to control this species. Applicant is requested to show any criticality which would not have been expected by knowing the teaching of the prior art.

Art Unit: 1616

Rejection of claims under 35 U.S.C. 103(a) as being unpatentable over CURTZE et al.
 (US Patent No. 6127570) is therefore maintained because arguments are not found persuasive. The basis of arguments is that prior does not teach the use of one compound is not considered appropriate because the term "comprising" allows the addition of other ingredients.

# **Double Patenting**

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1, 2, 4, and 5 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-5 of U.S. Patent No. 6,696,497. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims of the US Patents cited above are considered obvious since the term "comprising" is used in the instant invention. The term "comprising" allows other additional components to be added. The instant claims differ from the claims of the cited US Patents in that these US Patents cite specific second components for the fungicidal composition. In the instant claims, a specific second ingredient has not been named. However, the term "comprising" allows a second ingredient to be added. Therefore, the instant invention is considered obvious over the claims of the cited US Patents.

#### Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1, 2, 4, and 5 are rejected under 35 U.S.C. 103(a) as being unpatentable over CURTZE et al. (US Patent No. 6127570). CURTZE et al. teaches fungicidal substituted 2-hydroxybenzophenone compounds, which embraces the presently claimed invention. See the entire document, especially lines 7-34 in col. 3, lines 23-64 in col. 4, the abstract, claims (especially claim 1), and examples.

Art Unit: 1616

Instant claims differ from the prior art in claiming a narrower scope of the prior art's invention.

One skilled in the art would have been motivated to prepare a method for controlling Pseudocercosporella herpotrichoides in crop plants comprising applying to said crop plants an effective amount of benzophenones of the Formula I because the prior art teaches the control of fungus in crop plants through the use of benzophenone derivatives.

It would have been obvious to one skilled in the art at the time of invention to prepare similar benzophenones to control any fungus in crop plants because CURTZE et al. teaches the control of fungus in crop plants through the use of benzophenone derivatives, as claimed.

In absence of any criticality and/or unexpected results, the presently claimed invention is considered prima facie obvious to one skilled in the art.

In the light of the forgoing discussion, the Examiner's ultimate legal conclusion is that the subject matter defined by the instant claims would have been obvious within the meaning of 35 U.S.C. 103(a).

## **Contact Information**

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sabiha Qazi whose telephone number is (571) 272-0622. The examiner can normally be reached on any business day.

Application/Control Number: 10/616,950

Art Unit: 1616

Page 7

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Padmanabhan, Sreeni (acting) can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Tuesday, February 21, 2006

SABIHA QAZI, PH.D PRIMARY EXAMINER